Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

Endothelin B Receptor, a New Target in Cancer Immune Therapy

(2009) L. E. Kandalaft et al.   CLINICAL CANCER RESEARCH

Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study

(2008) Alexandros Daponte et al.   BMC CANCER

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH

Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1α

(2008) Jeremy Ben-Shoshan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells

(2008) Ilaria Marigo et al.   IMMUNOLOGICAL REVIEWS

Expression of hypoxia-inducible factor 1α gene affects the outcome in patients with ovarian cancer

(2007) R. SHIMOGAI et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE